ACR: Cycling JAK Inhibitors Feasible for Difficult-to-Treat RA

One-year outcomes similar for cycling JAK inhibitors versus switching to a biologic drug
a patient with a doctor
a patient with a doctor

Adobe Stock

Published on
Updated on

TUESDAY, Nov. 9, 2021 (HealthDay News) -- People with difficult-to-treat rheumatoid arthritis (RA) that does not respond to one Janus kinase inhibitor (JAKi) may achieve a similar response by either cycling to other JAKi medications or switching to a biologic drug, according to a study presented at the annual meeting of the American College of Rheumatology, held virtually from Nov. 3 to 9.

Manuel Pombo-Suarez, M.D., Ph.D., from Hospital Clinico Universitario of Santiago de Compostela in Spain, and colleagues compared the effectiveness of cycling JAKi versus switching to a biologic disease-modifying antirheumatic drug (bDMARD) in a real-world population of RA patients using data from 14 national registries participating in the JAK-pot collaboration. Analysis included 708 patients who failed JAKi (154 cycled to a second JAKi and 554 switched to a bDMARD).

The researchers found that patients cycling JAKi were older, had longer disease duration, had received more bDMARDs, and had longer exposure to first JAKi treatment versus those switching to a bDMARD. Discontinuation of the first JAKi was more often for safety reasons than for lack of effectiveness. At two years of follow-up, cycling and switching strategies showed similar drug survival rates. The Disease Activity Score 28 was similar between patients cycling JAKi and switching to a bDMARD, with improvements seen after one year of follow-up.

"After failing a first JAKi, cycling JAKi versus switching to a bDMARD appears to have similar effectiveness despite a more difficult to treat patient profile for the patients cycling to JAKi," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Press Release

More Information

Related Stories

No stories found.
logo
www.healthday.com